WO1996012813A1 - Promoter from a plant alpha-amylase gene - Google Patents

Promoter from a plant alpha-amylase gene Download PDF

Info

Publication number
WO1996012813A1
WO1996012813A1 PCT/EP1995/002195 EP9502195W WO9612813A1 WO 1996012813 A1 WO1996012813 A1 WO 1996012813A1 EP 9502195 W EP9502195 W EP 9502195W WO 9612813 A1 WO9612813 A1 WO 9612813A1
Authority
WO
WIPO (PCT)
Prior art keywords
promoter
plant
dna
present
goi
Prior art date
Application number
PCT/EP1995/002195
Other languages
French (fr)
Inventor
Jette Dina Kreiberg
Marianne Lund
Helle Frost PEDERSEN
Original Assignee
Danisco A/S
PEDERSEN, Rolf, Frost
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco A/S, PEDERSEN, Rolf, Frost filed Critical Danisco A/S
Priority to AU30750/95A priority Critical patent/AU3075095A/en
Publication of WO1996012813A1 publication Critical patent/WO1996012813A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2408Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411Amylases
    • C12N9/2414Alpha-amylase (3.2.1.1.)
    • C12N9/2422Alpha-amylase (3.2.1.1.) from plant source
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8222Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation
    • C12N15/8223Vegetative tissue-specific promoters
    • C12N15/8226Stem-specific, e.g. including tubers, beets

Definitions

  • the present invention relates to a promoter, including a construct and an expression vector comprising the same and a transformed cell comprising the same.
  • the present invention relates to a plant comprising the same.
  • a gene of interest (“GOI")
  • a GOI may be desirable to achieve expression of a GOI in certain tissues it is sometimes important (if not necessary) to ensure that the GOI is not expressed in other tissues in such a manner that detrimental effects may occur. Moreover, it is important not to upset the normal metabolism of the organism to such an extent that detrimental effects occur. For example, a disturbance in the normal metabolism in a plant's leaf or root tip could lead to stunted growth of the plant.
  • CA-A-2006454 describes a DNA sequence of an expression cassette in which the potato tuber specific regulatory regions are localised.
  • the expression cassette contains a patatin-gene with a patatin-gene promoter.
  • the DNA sequence is transferred into a plant genome using agrobacteria. According to CA-A-2006454, the DNA sequence enables heterologous products to be prepared in crops.
  • ⁇ -amylase participates in the pathway responsible for the breakdown of starch to reducing sugars in potato tubers.
  • Genes coding for ⁇ -amylase in potato plants have been isolated and characterised. For example, see the teachings in EP-B-0470145.
  • ⁇ -amylase is encoded by a gene family consisting of at least 5 individual genes. Based on their homology the genes can be divided into two subfamilies - one of which is the type 3 amylase(s), the other of which is the type 1 amylase(s). The two groups of ⁇ -amylases are expressed differently, not only on the molecular level but also in different tissues of the potato plant.
  • type 3 ⁇ -amylases are expressed in tubers, in sprouts and in stem tissue; whereas type 1 ⁇ -amylases are expressed in sprout and stem tissues, but not in tubers or roots or leaves.
  • the present invention seeks to provide a plant promoter that is capable of directing the expression of a gene of interest in specific tissues, or in just a specific tissue, of an organism, typically a plant.
  • a promoter comprising the sequence shown as Seq.I.D.No. 1 or a variant, homologue or fragment thereof.
  • a promoter comprising the sequence shown as Seq.I.D.No. 1 or a variant, homologue or fragment thereof but wherein at least a part of the promoter is inactivated.
  • a construct comprising the promoter according to the present invention fused to a GOI.
  • an expression vector comprising the promoter according to the present invention or the previous aspect of the present invention.
  • a transformation vector comprising the promoter according to the present invention or any one of the other previous aspects of the present invention.
  • a transformed cell comprising the promoter according to the present invention or any one of the other previous aspects of the present invention.
  • a transgenic organism comprising the promoter according to the present invention or any one of the other previous aspects of the present invention.
  • a promoter according to the present invention to direct expression of a GOI in sprout or, preferably, stem cell, tissue or organ of a plant.
  • aspects of the present invention include methods of expressing or transforming any one of the expression vector, the transformation vector, the transformed cell, including in situ expression within the transgenic organism, as well as the products thereof. Additional aspects of the present invention include uses of the promoters for expressing GOIs in vitro (e.g. in culture media such as a broth) and in vivo (e.g. in a transgenic organism).
  • the promoter is present in combination with at least one GOI.
  • the transformation vector is derived from agrobacterium.
  • the promoter is stably incorporated within the transgenic organism's genome.
  • the transgenic organism is a plant.
  • the plant is a dicot plant. More preferably, the plant is a potato plant.
  • a key advantage of the present invention is that the promoter having the sequence shown as Seq. I.D. No. 1 is able to direct expression of a GOI in sprout and stem tissue of a dicot, for example, a potato. The same is true for the variant, homologue or fragment thereof.
  • the promoter directs expression of a GOI in stem tissue.
  • promoter sequence can be truncated and it can still express a GOI.
  • the truncated promoter sequences can direct expression of a GOI in one specific tissue (i.e. sprout or stem, preferably stem) - rather than a combination of sprout and stem tissues.
  • a truncated version of the promoter sequence shown as Seq. I.D. No. 1 can direct expression of a GOI in just stem tissue or just sprout tissue. The same is true for variants, homologues or fragments thereof.
  • Tissue specific expression such as stem specific expression, is particularly advantageous for a number of reasons.
  • a GOI can be used to express a GOI to give resistance against diseases that affect stem tissue.
  • a known disease is black-leg which specifically affects potato stems and can produce soft rot in tubers (25).
  • black-leg which specifically affects potato stems and can produce soft rot in tubers (25).
  • a GOI coding for, for example, a toxin against the organism Erwinia carotovora causing the black-leg disease.
  • promoter is used in the normal sense of the art, e.g. an RNA polymerase binding site in the Jacob-Monod theory of gene expression.
  • the promoters of the present invention are capable of expressing a GOI.
  • the promoters of the present invention could additionally include conserved regions such as a Pribnow Box or a TATA box.
  • the promoters may even contain other sequences to affect (such as to maintain, enhance, decrease) the levels of expression of the GOI.
  • suitable other sequences include the Sh1-intron or an ADH intron.
  • Other sequences include inducible elements - such as temperature, chemical, light or stress inducible elements.
  • suitable elements to enhance transcription or translation may be present.
  • An example of the latter element is the TMV 5' leader sequence (sec Sleat Gene 217 [1987] 217-225; and Dawson Plant Mol. Biol. 23 [1993] 97).
  • the promoter of the present invention is sometimes refered to as the alpha-Amy 1 promoter or the Amy 1 promoter or the Amy 637 promoter.
  • a promoter of the present invention which may be a stem specific promoter, could be used with a tuber specific promoter.
  • Other combinations are possible.
  • the promoter of the present invention which may be stem or sprout specific promoter, could be used with a root tissue promoter and/or a leaf tissue promoter.
  • variant include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence has the ability to act as a promoter in an expression system -such as the transformed cell or transgenic organism according to the present invention.
  • homologue covers homology with respect to structure and/or function providing the resultant nucleotide sequence has the ability to act as a promoter. With respect to sequence homology, preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology, more preferably at least 95%, more preferably at least 98% homology.
  • inactivated means partial inactivation in the sense that the expression pattern of the promoter of Seq. I.D. No. 1 is modified but wherein the partially inactivated promoter still functions as a promoter.
  • the modified promoter is capable of expressing a GOI in at least one (but not all) specific tissue of the promoter of Seq. I.D. No. 1. Therefore with this particular aspect of the invention, the promoter having an inactivated portion can still function as a promoter (hence it is still called a promoter) but wherein the promoter is capable of expressing a GOI in one or more, but not all, of the tissues where a GOI is expressed by a promoter having the sequence shown as Seq. I.D. No. 1.
  • partial inactivation examples include altering the folding pattern of the promoter sequence, or binding species to parts of the nucleotide sequence, so that a part of the nucleotide sequence is not recognised by, for example, RNA polymerase.
  • Another, and preferable, way of partially inactivating the promoter is to truncate it to form fragments thereof. Anoter way would be to mutate at least a part of the sequence so that the RNA polymerase can not bind to that part or another part.
  • a promoter comprising a nucleotide sequence corresponding Seq.I.D. No. 1, or a variant, homologue or fragment thereof but wherein the promoter is truncated.
  • the term "truncated" includes shortened versions of the promoter shown as Seq. I.D. No. 1.
  • construct which is synonymous with terms such as “conjugate”, “cassette” and “hybrid” - includes a GOI directly or indirectly attached to the promoter.
  • An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Sh1-intron or the ADH intron, intermediate the promoter and the GOI.
  • suitable spacer group such as an intron sequence, such as the Sh1-intron or the ADH intron, intermediate the promoter and the GOI.
  • fused in relation to the present invention which includes direct or indirect attachment. In each case, it is highly preferred that the terms do not cover the natural combination of the wild type alpha amylase gene ordinarily associated with the wild type gene promoter and the wild type promoter and when they are both in their natural environment.
  • the construct may even contain or express a marker which allows for the selection of the genetic construct in, for example, a plant cell into which it has been transferred.
  • markers which may be used in, for example, plants - such as mannose.
  • Other examples of markers include those that provide for antibiotic resistance - e.g. resistance to G418, hygromycin, bleomycin, kanamycin and gentamycin.
  • the term "GOI" with reference to the present invention means any gene of interest.
  • a GOI can be any nucleotide that is either foreign or natural to the organism (e.g. plant) in question.
  • Typical examples of a GOI include genes encoding for proteins and enzymes that modify metabolic and catabolic processes.
  • the GOI may code for an agent for introducing or increasing pathogen resistance.
  • the GOI may even be an antisense construct for modifying the expression of natural transcripts present in the relevant tissues.
  • the GOI may even code for a non-natural plant compound that is of benefit to animals or humans.
  • the GOI could code for a pharmaceutically active protein or enzyme such as any one of the therapeutic compounds insulin, interferon, human serum albumin, human growth factor and blood clotting factors.
  • the transformed cell or organism could prepare acceptable quantities of the desired compound which would be easily retrievable from, for example, stem.
  • the GOI may even be a protein giving nutritional value to the plant as a food or crop. Typical examples include plant proteins that can inhibit the formation of anti-nutritive factors and plant proteins that have a more desirable amino acid composition (e.g. a higher lysine content than the non-transgenic plant).
  • the GOI may even code for an enzyme that can be used in food processing such as chymosin, thaumatin and alpha-galactosidase.
  • the GOI is a gene encoding for any one of a pest toxin, an antisense transcript such as that for patatin or alpha-amylase, ADP-glucose pyrophosphorylase (e.g. see EP-A-0455316), a protease antisense or a glucanase.
  • the term 'organism' in relation to the present invention includes any organism wherein the promoter can be activated.
  • the organism is an amylase (e.g. alpha-amylase) producing organism such as plants, algae, fungi and bacteria, as well as cell lines thereof.
  • the term means a plant or cell thereof, preferably a dicot, more preferably a potato.
  • the term 'transgenic organism' in relation to the present invention means an organism comprising either an expressable construct according to the present invention or a product of such a construct.
  • the transgenic organism can comprise an exogenous nucleotide sequence (e.g. GOI as herein described) under the control of a promoter according to the present invention; or a native nucleotide sequence under the control of a partially inactivated (e.g. truncated) promoter according to the present invention.
  • cell include cell, tissue and organ per se and when within an organism.
  • tissue include cell, tissue and organ per se and when within an organism.
  • the term preferably means a potato stem cell, tissue or organ and a potato sprout cell, tissue or organ for another class/type of promoters according to the present invention it preferably means potato sprout cell, tissue or organ or potato stem cell, tissue or organ.
  • the expressable construct is incorporated in the genome of the organism.
  • the term incorporated preferably covers stable incorporation into the genome.
  • 'nucleotide' in relation to the GOI includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA.
  • expression vector means a construct capable of in vivo or in vitro expression.
  • transformation vector means a construct capable of being transferred from one species to another - such as from an E.Coli plasmid to a plant cell, or from agrobacterium to a plant cell.
  • the basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material.
  • Several techniques exist for inserting the genetic information the two main principles being direct introduction of the genetic information and introduction of the genetic information by use of a vector system. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27).
  • the present invention relates to a vector system which carries a promoter or construct according to the present invention and which is capable of introducing the promoter or construct into the genome of a plant such as a plant of the family Solanaceae, in particular of the genus Solanum, especially Solanum tuberosum.
  • the vector system may comprise one vector, but comprises preferably two vectors; in the case of two vectors, the vector system is normally referred to as a binary vector system.
  • Binary vector systems are described in further detail in Gynheung An et al. (1980), Binary Vectors, Plant Molecular Biology Manual A3, 1-19.
  • One extensively employed system for transformation of plant cells with a given promoter or construct is based on the use of a Ti plasmid from Agrobacterium tumefaciens or a Ri plasmid from Agrobacterium rhizogenes An et al. (1986), Plant Physiol. 81, 301-305 and Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds.: D.S. Ingrams and J.P. Helgeson, 203-208.
  • Ti and Ri plasmids have been constructed which are suitable for the construction of the plant or plant cell constructs described above.
  • a non-limiting example of such a Ti plasmid is pGV3850.
  • the promoter or construct of the present invention should preferably be inserted into the Ti-plasmid between the terminal sequences of the T-DNA or adjacent a T-DNA sequence so as to avoid disruption of the sequences immediately surrounding the T-DNA borders, as at least one of these regions appear to be essential for insertion of modified T-DNA into the plant genome.
  • the vector system of the present invention is preferably one which contains the sequences necessary to infect a plant (e.g. the vir region) and at least one border part of a T-DNA sequence, the border part being located on the same vector as the genetic construct.
  • the vector system is preferably an Agrobacterium tumefaciens Ti-plasmid or an Agrobacterium rhizogenes Ri-plasmid or a derivative thereof, as these plasmids are well-known and widely employed in the construction of transgenic plants, many vector systems exist which are based on these plasmids or derivatives thereof.
  • the promoter or construct may be first constructed in a microorganism in which the vector can replicate and which is easy to manipulate before insertion into the plant.
  • An example of a useful microorganism is E. coli, but other microorganisms having the above properties may be used.
  • a vector of a vector system as defined above has been constructed in E. coli, it is transferred, if necessary, into a suitable Agrobacterium strain, e.g. Agrobacterium tumefaciens.
  • the Ti-plasmid harbouring the promoter or construct of the invention is thus preferably transferred into a suitable Agrobacterium strain, e.g. A.
  • cloning vectors which contain a replication system in E. coli and a marker which allows a selection of the transformed cells.
  • the vectors contain for example pBR 332, pUC series, M13 mp series, pACYC 184 etc.
  • the construct or promoter can be introduced into a suitable restriction position in the vector.
  • the contained plasmid is used for the transformation in E.coli.
  • the E.coli cells are cultivated in a suitable nutrient medium and then harvested and lysed.
  • the plasmid is then recovered.
  • a method of analysis there is generally used a sequence analysis, a restriction analysis, electrophoresis and further biochemical-molecular biological methods.
  • the used DNA sequence can be restricted and connected with the next DNA sequence.
  • Each sequence can be cloned in the same or different plasmid.
  • further DNA sequences may be necessary. If for example for the transformation, the Ti- or Ri-plasmid of the plant cells is used, at least the right boundary and often however the right and the left boundary of the Ti- and Ri-plasmid T-DNA, as flanking areas of the introduced genes, can be connected.
  • T-DNA for the transformation of plant cells is being intensively studied and is well described in EP 120 516; Hockcma, in: The Binary Plant Vector System Offset-drukkerij Kanters B.B., Alblasserdam, 1985, Chapter V; Fraley, et al., Crit. Rev. Plant Sci., 4:1-46 and An et al., EMBO J. (1985) 4:277-284.
  • Direct infection of plant tissues by Agrobacterium is another simple technique which may be employed.
  • a plant to be infected is wounded, e.g. by cutting the plant with a razor or puncturing the plant with a needle or rubbing the plant with an abrasive.
  • the wound is then inoculated with the infection of a plant may be done on a certain part or tissue of the plant, i.e. on a part of a leaf, a root, a stem or another part of the plant.
  • the inoculated plant or plant part is then grown on a suitable culture medium and allowed to develop into mature plants.
  • tissue culturing methods such as by culturing the cells in a suitable culture medium supplied with the necessary growth factors such as amino acids, plant hormones, vitamins, etc.
  • Regeneration of the transformed cells into genetically modified plants may be accomplished using known methods for the regeneration of plants from cell or tissue cultures, for example by selecting transformed shoots using an antibiotic and by subculturing the shoots on a medium containing the appropriate nutrients, plant hormones, etc.
  • the present invention therefore relates to a promoter and, also to a construct comprising the same.
  • the present invention relates to the use of a promoter for the expression of a GOI in an cell/tissue/organ/ organism such as one or more specific tissues of a plant, in particular a dicot plant such as a potato.
  • the present invention relates to a partially inactivated (such as truncated) type 1 ⁇ -amylase promoter.
  • the present invention also relates to the application of one class of partially inactivated gene promoters to express a GOI specifically in at least the stem or sprout tissue of a dicot - especially a potato plant.
  • NCIMB National Collections of Industrial and Marine Bacteria Limited
  • DH5alpha-gPAmy 637 (Deposit number NCIMB 40683) This deposited sample is an E. Coli bacterial stock containing the plasmid pBluescript (see Figure 6 for general map thereof) containing the promoter of SEQ. I.D. No. 1 - i.e. the Amy 1 promoter. Details on how the plasmid was formed are given later.
  • Figure 1 shows Southern blots for restiction enzyme digests of a clone according to the present invention ( Figures 1A and 1B);
  • Figure 2 shows a restriction map of a clone according to the present invention
  • Figure 3 is a sequence map of a clone according to the present invention
  • Figure 4 is the nucleotide sequence of a promoter according to the present invention
  • Figure 5 shows the primer sequences for use in the present invention
  • Figure 6 is a plasmid map of pBlueScript KS- (2.96 kb).
  • Figures 1A and 1B are gel patterns of digested DNA of the lamda 637 clone;
  • Plant material Root tissue were harvested from flowering potato (Solanum tuberosum, cv. Satuma) plants. The roots were sliced directly into liquid nitrogen and 10-15g portions were stored at -80°C until use. Bacterial strains
  • 10 ⁇ HB 40mM spermidine, 10mM spermine, 0.1mM Na 2 -EDTA, 0.1mM Tris, 0.8mM KCl, adjusted to pH 9.4-9.5 with 10N NaOH.
  • PMSF phenylmethylsulfonyl fluoride dissolved in ethanol).
  • the resuspended plant material was filtered through a 70 ⁇ m nylon filter (Nitex filter, prewetted in 1xH buffer). The resulting filtrate was poured into two centrifuge bottles (Sorvall GSA) and the nuclei pelleted at 4000 r.p.m for 20 min at 4°C. The supernatant was discarded and the pellets were gently resuspended by adding 20 ml 1 ⁇ H buffer per tube and then swirling the tubes carefully. The nuclei were pelleted again at 4000 r.p.m. for 20 min at 4°C, the supernatant removed and the pellets resuspended gently in 10 ml 1 ⁇ H buffer.
  • the supernatant was pooled and 20 ml cold lysis buffer (lysis buffer: 2% Sarcosyl, 0.1M Tris, 0.04M Na 2 -EDTA) was added dropwise while the solution was stirred gently. Immediately after the last drop of lysis buffer was added, 0.972g CsCl/ml solution was stirred gently into the solution (the solution should now be at room temperature). The resulting solution was centrifuged for 45 min at 10 krpm, 4°C. The supematants were carefully removed using a pasteur pipet avoiding any protein debris floating on the top or disturbing the pellets. The volume of the supematants were determined and 0.2 mg ethidium bromide/ml was added.
  • lysis buffer 2% Sarcosyl, 0.1M Tris, 0.04M Na 2 -EDTA
  • the DNA solution was then gently poured into quickseal polyallomer tubes, which were then sealed.
  • the tubes were centrifuged in a Beckman VTI 65 rotor at 18°C and 40 k r.p.m. for 38 h.
  • the genomic band was removed under UV-light with a 15-18 gauge needle attached to a 5-ml syringe and poured gently into a 5 ml polyallomer tube.
  • the tube(s) was filled with a 1.57 g/ml CsCl solution in 50mM Tris-Hcl(pH 9.5), 20 mM Na 2 -EDTA. 75 ⁇ l ethidium bromide (5mg/ml) was added/tube.
  • the tubes were centrifuged in the VTI 65 rotor at 18°C and 46 krpm for 17 h.
  • the genomic band was removed under long-wave UV light and the ethidium bromide was extracted with CsCl-saturated isopropanol (7 to 8 times).
  • the CsCl was removed from the DNA by dialysis in TE-buffer (1 ⁇ TE: 10 mM Tris-HCl, 1 mM Na 2 -EDTA pH 8.0) at 4°C for 18 h with three changes.
  • the high MW genomic potato DNA was not further precipitated and was kept at 4°C.
  • High MW genomic potato DNA was prepared from cv Satuma roots as decribed above. The quality of the DNA was tested by restriction enzyme digestion and gel electrophoresis.
  • genomic DNA was partially digested with Sau3A and the created fragments (9-23 kb) were inserted into the BamHI site of the ⁇ EMBL3 vector (4). Approximately 1.1 ⁇ 10 6 independent isolates were plated and amplified to form a permanent library (7).
  • Plaque hybridization was used to screen the library for ⁇ -amylase genes. Screening of the library
  • Each plate contained approximately 2 ⁇ 10 5 plaques, which were mixed with 1 ml of infection competent cells (prepared as above) and incubated for 20 min at 37°C. This mixture was then added to a 25 ml of warm (42-45°C) 0.3% top agarose with 10 mM MgCl 2 and the solution was poured onto a fresh dry LB plate. The large LB plates were incubated (not upside down) overnight at 37°C. Phages from the plaques were transferred to Hybond N filters (Amersham) in duplicates. The plates were placed at 4°C for 1 to 2 h to prevent the agarose layer from sticking to the filters. The plates were placed on ice, just before use and they remained on the ice when working with the filters.Two Hybond N filters and a plate were marked for orientation of the filters .
  • the first filter was laid on the plaques for 45 sec; then floated on denaturation buffer (0.5 M NaOH, 1.5 M NaCl) for 7 min, with the phages facing up, then floated on neutralization buffer (0.5 M Tris-HCl (pH 7.4), 3 M NaCl) for 2 times 3 min and finally washed in 2 ⁇ SSC (1 ⁇ SSC: 0.15 M NaCl, 0.015 Na-citrate).
  • the filter was air dried and the phage DNA was fixed to the membrane by UV crosslinking.
  • the second filter was laid on the same plate, after the first, for 120 sec and then treated as the first. These filters were used in plaque hybridization following the Hybond N membrane protocol according to suppliers (Amersham) instructions. X-ray film from both the first and second Hybond N membrane was orientated so that the signals from both filters fitted each other.
  • the positive plaques were cut with a scalpel (1 ⁇ 1 cm blocks) and submerged in 1 ml phage buffer.
  • the phage containing tubes were stored airtight (parafilm) at 4°C after 2-3 drops of chloroform has been added.
  • the plaque containing plates (22 ⁇ 22 cm) were stored by placing a piece of soaked (chloroform) filterpaper in the lid. The plates were also stored airtight at 4°C with the plaques facing up. Further purification of the positive plaques were done by plating dilutions of the stock tube (containing the 1 ⁇ 1 cm block) with freshly prepared cells and plate them on round LB plates with 1% warm (42°C) top-agar and 10 mM MgCl 2 . New filter prints were made with Hybond N following the procedure outlined above with the 22 ⁇ 22 cm plates.
  • Plaques which gave positive signal were isolated by sticking the tip of a pasteur pipette though the plate and transfer it to 500 ⁇ l phagebuffer. New series of dilutions were made, plated and the respective filters hybridized until the positive plaques were purified. The phages were stored airtight, at 4°C either in the 500 ⁇ l phagebuffer with 1 drop of chloroform, or as phages isolated from a plate lysate.
  • the plate lysate stock was made as decribed by (9).
  • A) LE392 cells were inoculated in LB with 0.2% maltose and 10 mM MgCl 2 and grown O/N at 37°C. The cells were pelleted by centrifugation for 10 min, at 4°C in a Sorvall centrifuge, and resuspended gently in 1 volume of cold 10 mM MgSO 4 . The cells were stored at 4°C until use. Five single plaques from a plate were transferred to 500 ⁇ l phagebuffer and allowed to stand for 2-21 ⁇ 2 h at 4°C.
  • the solution was incubated 30 min at 37°C and then 1 volume of cold 20% PEG, 2 M NaCl mixed in phagebuffer was added and the mixture was incubated 1 h on ice.
  • the phages were pelleted by centrifugation for 20 min, 4°C at 10 krpm.
  • the PEG pellet was resuspended in 400 ⁇ l phagebuffer and transferred to an eppendorf tube. 1 ⁇ l of RNase (10 mg/ml) is added and the tube incubated for 30 min at 37°C. Then 8 ⁇ l 0.25 M Na 2 -EDTA, pH 8.0 and 4 ⁇ l 10% SDS was added, the tube was incubated a further 15 min at 68°C.
  • the mixture was allowed to gain room temperature and then an equal phenol saturated with TE-buffer (1 ⁇ TE: 10 mM Tris pH 7.5, 1 mM Na 2 -EDTA) was used to extract the DNA.
  • a equal mixture of saturated phenol-chloroform was used to extract the upper aqueous phase and a final chloroform extraction was done.
  • the upper phase was transferred to a new tube and the solution was made 0.3 M Na-acetate and 2-3 vol cold ethanol was added.
  • the precipitation of the DNA was accomplished by storing at O/N at -20°C, centrifuging for 5 min and resuspend the pellet in 50-100 ⁇ l TE-buffer.
  • the amount and quality of the recombinant phage DNA was tested by restrictions enzyme digest and agarose (0.8-1%) gel electrophoresis (11).
  • the plasmid preparation was as described in EP-B-0470145.
  • small scale preparation of plasmid DNA was performed as follows.
  • Bacterial strains harbouring the plasmids were grown overnight in 2 ml L-Broth (LB) medium with ampicillin added (35 ⁇ g/ml). The operations were performed in 1.5 ml Eppendorf tubes and centrifugation was carried out in an Eppendorf centrifuge at 4°C. The cells from the overnight culture were harvested by centrifugation for 2 min., washed with 1 ml 10 mM Tris-HCl (pH 8.5), 50 mM EDTA and centrifuged for 2 min. The pellet was suspended in 150 ⁇ l of 15% sucrose, 50 mM Tris-HCl (pH 8.5), 50 mM EDTA by vortexing.
  • Precipitation was accomplished by storing at either 5 min. at -80°C or O/N at -20°C, centrifuging for 5 min., drying by vacuum for 2 min. and redissolving the pellet in 20 ⁇ l H 2 O. The yield was 5-10 ⁇ g plasmid DNA.
  • Large scale preparation of plasmid DNA was accomplished by simply scaling up the small scale preparation ten times. Working in 15 ml corcx tubes, all the ingredients were scaled up ten times.
  • the centrifugation was carried out in a Sorvall cooling centrifuge at 4°C. Only changes from the above will be mentioned in the following. After incubation at 70-72°C, the centrifugation was for 30 min. at 17,000 rpm. After adding isopropanol and after adding cold ethanol, the centrifugation was for 15 min. at 17,000 rpm.
  • the final plasmid DNA pellet was then suspended in H 2 O and transferred to an Eppendorf tube and then given a short spin to remove debris. The supernatant was adjusted to 0.3 M Na-acetate and 2-3 vol. cold ethanol were added. The pellet was resuspended in 40 ⁇ l H 2 O. The yield was usually 20-28 ⁇ g plasmid DNA.
  • the banded plasmid DNA was withdrawn from the tubes using a syringe and the ethidium bromide was extracted with CsCl-saturated isopropanol 7-8 times.
  • the CsCl was removed by dialysis in 10 mM Tris-HCl (pH 8.0), 1 mM EDTA for 48 hours with three changes of buffer.
  • the DNA was precipitated by adjusting to 0.3 M Na-acetate and adding 2-3 vol. cold ethanol.
  • the small scale plasmid preparation from E. coli was usually followed by a LiCl precipitation to remove RNA from the DNA solution.
  • the small scale prepared plasmid DNA was dissolved in 100 ⁇ l destilled water.
  • a random primed DNA labelling kit (Boehringer Mannheim) was used according to the suppliers instructions. Briefly, 2 ⁇ l DNA fragment (25-50 ng) is mixed with 8 ⁇ l H 2 O and incubated at 95°C for 10 min to denature the DNA. Spin shortly and place on ice. Then add 1 ⁇ l dGTP, dATP and dTTP of each, 2 ⁇ l reactionsmix and 5 ⁇ l (approx. 50 ⁇ Ci dCTP 32 ). 1 ⁇ l Klenow enzyme starts the reaction and the tube is incubated at 37°C for 30 min. Then place on ice. The labelled DNA fragment was purified using an ELUTIP column (Schleicher & Schuell).
  • the column was prepared by prerunning (gravity) it with 3 ml high salt buffer (1.0 M NaCl, 20 mM Tris-HCl (pH 7,5), 1.0 mM EDTA), followed by 5 ml low salt buffer (0.2 M NaCl, 20 mM Tris-HCl (pH 7,5), 1.0 mM EDTA). 250 ⁇ l low salt was added to the labelling tube and the entire solution was laid on the prepared column. Then the column was washed with 2x400 ⁇ l low salt followed by 3 ⁇ 200 ⁇ l high salt. The eluted radioactive probe was then heat denatured and used in hybridization.
  • the DNA fragments to be transferred were fractionated on non-denaturing agarose gels (109) and transferred to either HybondTM N or HybondTM N+, positively charged nylon membrane (Amersham Life Science) by Southern blotting (12,13). Hybridization to the HybondTM N nylon membranes was followed according to the supplier's instructions (13).
  • Vectors (pBS-/+ or pBSK-/+) were digested with one or two restriction enzymes, extracted twice with saturated phenol (the phenol was first mixed with 0.1 M Tris-HCl, then mixed twice with TE-buffer (10 mM Tris-HCl, pH 8, 1 mM Na 2 -EDTA)) and once with chloroform and precipitated with 0.3 M Na-acetate and 2.5 vol cold ethanol. The pellet was rinsed in 70% cold ethanol and dissolved in H 2 O, giving a concentration of 25-50 ng/ ⁇ l. The vectors were tested for background before use (sclf-ligation with and without T4-DNA-ligase). If necessary the vector was treated with Alkaline phosphatase (Boehringer Mannheim) as described by the supplier. After such a treatment the resulting pellet was resuspended in H 2 O to give a final concentration of 10 ng/ ⁇ l.
  • the phage DNA or plasmid comprising a fragment to be subcloned was digested with one or more restriction enzymes and run in either a 5% aerylamide gel or an appropriate agarose gel.
  • the fragment to be subcloned was isolated from the gel either by electroelution as decribed in (109) or using a GENECLEAN II Kit (BIO 101 Inc., La Jolla, California) following the suppliers instructions.
  • Various ratios of fragment to vector were used (from 2:1 to 5:1, based on the number of molecules) in the ligation reaction.
  • 1 ⁇ l (10-100 ng) of a solution containing the vector was combined with the fragment, 1 ⁇ l of T4-ligation buffer (10 ⁇ (20 mM Tris-HCl, pH 7.6, 10 mM MgCl 2 , 0.6 mM ATP, 10 mM dithiotheitol)) and 1 ⁇ l of T4-DNA ligase (Boehringer Mannheim) were added to a mixture of fragment and vector to a total volume of 10 ⁇ l.
  • the reaction was incubated at 15°C O/N if the ligated DNA fragments had sticky ends. If the DNA had blunt ends, the incubation was at room temperature for 1 hour.
  • the ligation mixture was stored at -20°C if not used immediately, usually 5 ⁇ l of the ligation mix was used for transformation.
  • JM109 cells (or DH5 ⁇ ) were inoculated in 4 ml L-Broth made to 10 mM MgSO 4 and 10 mM MgCl 2 .
  • the cells were grown O/N at 37°C. 1 ml of the O/N culture was added to 40 ml prewarmed (37°C) LB medium (with 10 mM MgSO 4 and 10 mM MgCl 2 ). The culture was shaken at 250-275 rpm for 1 to 2 h until the OD 450 reached 0.8-0.9.
  • the cells were harvested by centrifugation at 5000 rpm for 10 min at 4°C.
  • the pellet was gently resuspended in 30 ml of cold 0.1 M CaCl 2 , another centrifugation pelleted the cells again and they were then resuspended in 15 ml of cold 0.1 M CaCl 2 .
  • the suspension was placed on ice for 20 min followed by a centrifugation as before.
  • the cells were gently resuspended in 3 ml of cold 0.1 M CaCl 2 and placed on ice for at least 1 h before they were ready to use for transformation (14).
  • the mixture was allowed to stand for at least 40 min on ice, then 5 min at 37°C (or 2 min at 42°C).
  • the solution was transferred to 0.8 ml of L-Broth, 10 mM MgSO 4 , 10 mM MgCl 2 , and incubated for 45 min at 37°C and then plated out on 5 AXI or other plates (as e.g. Amp-plates) at 0.2 ml/plate.
  • the plates were allowed to stand 10 min before being inverted and incubated O/N at 37°C.
  • the primer was synthesized on a polystyrene support column (Applied Biosystems, 393 DNA/RNA Synthesizer) and was eluted from the column with NH 4 OH.
  • the column was broken open and 1.5 ml NH 4 OH was added to the polystyrene material in a small glass tube.
  • the mixture was incubated at 85°C for 1 hour followed by 5 min on ice.
  • the supernatant containing the single stranded DNA was transferred to eppendorf tubes, and the NH 4 OH was evaporated in a vacuum centrifuge for at least 3 h.Pellet was resuspended in 200 ⁇ l destilled water and precipitated with 550 ⁇ l ethanol and 20 ⁇ l sodium acetate.
  • the pellet was resuspended in 200 ⁇ l water and precipitation with ethanol and sodium acetate was repeated. Finally the pellet was resuspended in 100 - 200 ⁇ l destilled water and the OD 260nm was measured by a Gene Quant RNA/DNA calculator (Pharmacia) of single stranded DNA is calculated. An OD 260nm of 1 corresponds approx. to 33 ⁇ g/ml single stranded DNA.
  • Purified ⁇ DNA was digested with appropiate restrictions enzymes and the generated fragments were isolated from agarose gels using a GeneClean Kit (BIO 1 Inc., La Jolla, California) according to the suppliers instructions.
  • Genomic DNA fragments (or fragments obtained from plasmids) were ligated into the polylinker region of the BlueScribe vector pBS-/+ (or pBSK-/+, Stratagene). After transforming an E. coli strain with the ligated plasmid the recombinant subclones could be selected by plating on AXI plates (they will be white and the nonrecombinant clones will be blue when the vector is a pBlueScribe plasmid,(5)).
  • Plasmid DNA from putative subclones were digested with appropiate restriction enzymes, subjected to gelelctrophoresis and after Soutern blotting, hybridized with an appropiate labelled DNA probe, to verify the origin of the inserted fragment.
  • the generated pBS genomic DNA subclones were then sequenced according to the plasmid preparation protocol outlined in EP-B-0470145.
  • the plasmid (double stranded template) to be sequenced was purified by the plasmid small scale preparation method.
  • the DNA was denatured in 0.2 M NaOH (5 min at room temperature) the mixture was neutralised by adding 0.4 vol of 5 M ammonium acetate (pH 7.5) and then precipitated with 4 vol. of cold ethanol (5 min at -80°C). The pellet was rinsed with 70°C cold ethanol and resuspended in 10 ⁇ l H 2 O.
  • Sequencing was accomplished with a SequenaseTM DNA Sequencing Kit from United States Biochemical Corp., following the sequencing Protocol enclosed in the kit (SequenaseTM :Step by Step Protocols for DNA sequencing with Sequenase, 3rd Edition, United States Biochemical Corporation PO Box 22400 Cleveland Ohio 44122).
  • T3 and T7 primers In addition to T3 and T7 primers (Stratagene) a whole range of other primers generated on a DNA synthesizer (Applied Biosystems, 392 DNA/RNA Synthesizer) were used. 0.5 pmol of primer was used to sequence 1 pmol of plasmid. The primer sequences are shown in the attached Figure 5.
  • the sequencing reactions were subjected to electrophoresis on 6 % or 8 % denaturing polyacrylamide gels for 1 to 4 hours at 40 W, then dried by a gel drier and autoradiographed for 3-48 hours at room temperature.
  • the denaturing sequencing gels were made from pre-mixed polyacrylamide solutions , Gel-Mix 6 and Gel-Mix 8 (GIBCO BRL, Life technologies, Inc) according to the manufacturers instructions.
  • 1.6 ⁇ 10 6 phages were carried out as decribed in Materials and Methods. Twenty four positive plaques were isolated and ⁇ DNA (see “Materials and Methods") was made from 8 of them. A SalI digest (release the inserted genomic fragment from the ⁇ arms) showed that the 8 clones contain genomic fragments ranging from approx 10.5 kb to 13.5 kb in size.
  • the clone gPAmy637 was chosen for further analysis by Southern blotting and hybridizations.
  • the ⁇ -amylase clones pAmyZ6 and pAmyZ1 contain sequences encoding an ⁇ -amy 1 type of ⁇ -amylase. They are however, not identical and using both for hybridizations to Southern blots which contain EcoRI, HindIII and BamHI digests of the gPAmy637 clone, revealed a slightly different hybridization pattern between them (sec Figure 1A and 1B).
  • Prominent hybridizing bands (called B1 and B2 in the BamHI digested lane, H1 and H2 in the HindIII digested lane and, E1 and E2 in the EcoRI digested lane, Figure 1) from all three digests of gPAmy637 were subcloned into pBS and pBSK vectors predigested with appropiate enzymes. Plasmid DNA isolated from transformed E.coli cells (see Material and Methods) were digested with appropiate restriction ezymes and used for Southern analysis using the insert of pAmyZ6 (it was cut out of the pBSK plasmid using AccI and SacI) as probe, to verify their origin.
  • a BamHI map of the gPAmy637 ⁇ clone is shown in Figure 2. This map covers approx. 2/3 of the genomic DNA insert in the clone (insert size approx. 13.5 kb).
  • Subcloninp a genomic fragment containing an a-amvlase promoter from potato
  • the B2-7 genomic fragment (see Figures 1 and 2) of 3763 bp was subcloned from gPAmy637 into a dephosphorylated BamHI site of a pBKS- vector (see Materials and Methods).
  • This subclone contains the ATG initiation codon, 1669 bp downstream of it covering approx. half of the structural gene and 2094 bp upstream covering the promoter region of the ⁇ -amy 1 type ⁇ -amylase gene.
  • the sequence region upstream of the ATG initiation codon covering about 1000-1500 bp include the entire promoter, enough to mediate transcription of the gene at the right time and place.
  • the sequence of the BamHI subclone (B2-7) isolated from gPAmy637 was determined (see Materials and Methods). This covers in total 3763 bp and the sequence map is shown in figure 3. The individual primer used is indicated in Figure 3 and corresponds to the list given in figure 5. The DNA sequence of the 2094 bp promoter region is shown in Figure 4. The promoter sequence was compared with published sequences in the EMBL database (using a PC-gene program from IntelliGenetics, Inc., California) and no sequence with significant overall homology was found.
  • TATA- and CAAT- boxes are underlined in Figure 4 and possible CAP sites are also indicated. Their positions correspond to the positions they are found in other eucaryotic polymerase II promoters (23-24).
  • ⁇ -amylase type 1 gene(s) is weakly expressed in potato sprouts. However, it is more strongly expressed in potato stems. This type is not found in leaves, tuber or root tissues.
  • the applicability of the promoters of the present invention is widespread. With the promoters it is possible to direct the expression of proteins into different tissues in the potato plant. It would also be possible to direct the expression of proteins into different tissues in other dicot plants.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A promoter is described that is capable of expresisng a GOI in any one of sprout and, preferably, stem tissue of a dicot plant. In particular, the promoter is a promoter for alpha-amylase.

Description

Promoter from a plant alpha-amylase gene
The present invention relates to a promoter, including a construct and an expression vector comprising the same and a transformed cell comprising the same. In addition the present invention relates to a plant comprising the same.
It is known that it is desirable to direct expression of a gene of interest ("GOI") in certain tissues of an organism - such as a plant. For example, it may be desirable to produce crop protein products with an optimised amino acid composition and so increase the nutritive value of the crop. It may even be desirable to use the crop to express non-plant genes such as genes for mammalian products. Examples of the latter products include interferons, insulin, blood factors and plasminogen activators.
However, whilst it may be desirable to achieve expression of a GOI in certain tissues it is sometimes important (if not necessary) to ensure that the GOI is not expressed in other tissues in such a manner that detrimental effects may occur. Moreover, it is important not to upset the normal metabolism of the organism to such an extent that detrimental effects occur. For example, a disturbance in the normal metabolism in a plant's leaf or root tip could lead to stunted growth of the plant.
CA-A-2006454 describes a DNA sequence of an expression cassette in which the potato tuber specific regulatory regions are localised. The expression cassette contains a patatin-gene with a patatin-gene promoter. The DNA sequence is transferred into a plant genome using agrobacteria. According to CA-A-2006454, the DNA sequence enables heterologous products to be prepared in crops.
One of the key plant enzymes is α-amylase. α-amylase participates in the pathway responsible for the breakdown of starch to reducing sugars in potato tubers. Genes coding for α-amylase in potato plants have been isolated and characterised. For example, see the teachings in EP-B-0470145. In brief, α-amylase is encoded by a gene family consisting of at least 5 individual genes. Based on their homology the genes can be divided into two subfamilies - one of which is the type 3 amylase(s), the other of which is the type 1 amylase(s). The two groups of α-amylases are expressed differently, not only on the molecular level but also in different tissues of the potato plant.
In this regard, type 3 α-amylases are expressed in tubers, in sprouts and in stem tissue; whereas type 1 α-amylases are expressed in sprout and stem tissues, but not in tubers or roots or leaves.
The present invention seeks to provide a plant promoter that is capable of directing the expression of a gene of interest in specific tissues, or in just a specific tissue, of an organism, typically a plant. According to a first aspect of the present invention there is provided a promoter comprising the sequence shown as Seq.I.D.No. 1 or a variant, homologue or fragment thereof.
According to a second aspect of the present invention there is provided a promoter comprising the sequence shown as Seq.I.D.No. 1 or a variant, homologue or fragment thereof but wherein at least a part of the promoter is inactivated.
According to a third aspect of the present invention there is provided a construct comprising the promoter according to the present invention fused to a GOI.
According to a fourth aspect of the present invention there is provided an expression vector comprising the promoter according to the present invention or the previous aspect of the present invention. According to an fifth aspect of the present invention there is provided a transformation vector comprising the promoter according to the present invention or any one of the other previous aspects of the present invention. According to a sixth aspect of the present invention there is provided a transformed cell comprising the promoter according to the present invention or any one of the other previous aspects of the present invention. According to a seventh aspect of the present invention there is provided a transgenic organism comprising the promoter according to the present invention or any one of the other previous aspects of the present invention.
According to an eighth aspect of the present invention there is provided the use of a promoter according to the present invention to direct expression of a GOI in sprout or, preferably, stem cell, tissue or organ of a plant.
Other aspects of the present invention include methods of expressing or transforming any one of the expression vector, the transformation vector, the transformed cell, including in situ expression within the transgenic organism, as well as the products thereof. Additional aspects of the present invention include uses of the promoters for expressing GOIs in vitro (e.g. in culture media such as a broth) and in vivo (e.g. in a transgenic organism).
Preferably, in any one of the expression vector, the transformation vector, the transformed cell or the transgenic organism the promoter is present in combination with at least one GOI.
Preferably the transformation vector is derived from agrobacterium. Preferably the promoter is stably incorporated within the transgenic organism's genome.
Preferably the transgenic organism is a plant. Preferably the plant is a dicot plant. More preferably, the plant is a potato plant. A key advantage of the present invention is that the promoter having the sequence shown as Seq. I.D. No. 1 is able to direct expression of a GOI in sprout and stem tissue of a dicot, for example, a potato. The same is true for the variant, homologue or fragment thereof. Preferably, the promoter directs expression of a GOI in stem tissue.
Further surprising however is the fact that the promoter sequence can be truncated and it can still express a GOI.
More surprising is the fact that the truncated promoter sequences can direct expression of a GOI in one specific tissue (i.e. sprout or stem, preferably stem) - rather than a combination of sprout and stem tissues. In this regard, a truncated version of the promoter sequence shown as Seq. I.D. No. 1 can direct expression of a GOI in just stem tissue or just sprout tissue. The same is true for variants, homologues or fragments thereof.
Tissue specific expression, such as stem specific expression, is particularly advantageous for a number of reasons.
In particular, it can be used to express a GOI to give resistance against diseases that affect stem tissue. For example, a known disease is black-leg which specifically affects potato stems and can produce soft rot in tubers (25). To improve the resistance in a potato crop against black-leg or any other disease which affect potato stems, it is possible to combine with the promoter of the present invention with a GOI coding for, for example, a toxin against the organism Erwinia carotovora causing the black-leg disease.
Highly preferred embodiments of each of the aspects of the present invention do not include the native promoter in its natural environment.
The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase binding site in the Jacob-Monod theory of gene expression. The promoters of the present invention are capable of expressing a GOI.
In addition to the nucleotide sequences described above, the promoters of the present invention could additionally include conserved regions such as a Pribnow Box or a TATA box. The promoters may even contain other sequences to affect (such as to maintain, enhance, decrease) the levels of expression of the GOI. For example, suitable other sequences include the Sh1-intron or an ADH intron. Other sequences include inducible elements - such as temperature, chemical, light or stress inducible elements. Also, suitable elements to enhance transcription or translation may be present. An example of the latter element is the TMV 5' leader sequence (sec Sleat Gene 217 [1987] 217-225; and Dawson Plant Mol. Biol. 23 [1993] 97). The promoter of the present invention is sometimes refered to as the alpha-Amy 1 promoter or the Amy 1 promoter or the Amy 637 promoter.
In addition the present invention also encompasses combinations of promoters or elements. For example, a promoter of the present invention, which may be a stem specific promoter, could be used with a tuber specific promoter. Other combinations are possible. For example, the promoter of the present invention, which may be stem or sprout specific promoter, could be used with a root tissue promoter and/or a leaf tissue promoter.
The terms "variant", "homologue" or "fragment" include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence has the ability to act as a promoter in an expression system -such as the transformed cell or transgenic organism according to the present invention. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence has the ability to act as a promoter. With respect to sequence homology, preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology, more preferably at least 95%, more preferably at least 98% homology.
The term "inactivated" means partial inactivation in the sense that the expression pattern of the promoter of Seq. I.D. No. 1 is modified but wherein the partially inactivated promoter still functions as a promoter. However, as mentioned above, the modified promoter is capable of expressing a GOI in at least one (but not all) specific tissue of the promoter of Seq. I.D. No. 1. Therefore with this particular aspect of the invention, the promoter having an inactivated portion can still function as a promoter (hence it is still called a promoter) but wherein the promoter is capable of expressing a GOI in one or more, but not all, of the tissues where a GOI is expressed by a promoter having the sequence shown as Seq. I.D. No. 1.
Examples of partial inactivation include altering the folding pattern of the promoter sequence, or binding species to parts of the nucleotide sequence, so that a part of the nucleotide sequence is not recognised by, for example, RNA polymerase. Another, and preferable, way of partially inactivating the promoter is to truncate it to form fragments thereof. Anoter way would be to mutate at least a part of the sequence so that the RNA polymerase can not bind to that part or another part.
Accordingly, for a preferred embodiment of the present invention there is provided a promoter comprising a nucleotide sequence corresponding Seq.I.D. No. 1, or a variant, homologue or fragment thereof but wherein the promoter is truncated. The term "truncated" includes shortened versions of the promoter shown as Seq. I.D. No. 1.
The term "construct" - which is synonymous with terms such as "conjugate", "cassette" and "hybrid" - includes a GOI directly or indirectly attached to the promoter. An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Sh1-intron or the ADH intron, intermediate the promoter and the GOI. The same is true for the term "fused" in relation to the present invention which includes direct or indirect attachment. In each case, it is highly preferred that the terms do not cover the natural combination of the wild type alpha amylase gene ordinarily associated with the wild type gene promoter and the wild type promoter and when they are both in their natural environment.
The construct may even contain or express a marker which allows for the selection of the genetic construct in, for example, a plant cell into which it has been transferred. Various markers exist which may be used in, for example, plants - such as mannose. Other examples of markers include those that provide for antibiotic resistance - e.g. resistance to G418, hygromycin, bleomycin, kanamycin and gentamycin. The term "GOI" with reference to the present invention means any gene of interest. A GOI can be any nucleotide that is either foreign or natural to the organism (e.g. plant) in question. Typical examples of a GOI include genes encoding for proteins and enzymes that modify metabolic and catabolic processes.
The GOI may code for an agent for introducing or increasing pathogen resistance. The GOI may even be an antisense construct for modifying the expression of natural transcripts present in the relevant tissues.
The GOI may even code for a non-natural plant compound that is of benefit to animals or humans. For example, the GOI could code for a pharmaceutically active protein or enzyme such as any one of the therapeutic compounds insulin, interferon, human serum albumin, human growth factor and blood clotting factors. In this regard, the transformed cell or organism could prepare acceptable quantities of the desired compound which would be easily retrievable from, for example, stem. The GOI may even be a protein giving nutritional value to the plant as a food or crop. Typical examples include plant proteins that can inhibit the formation of anti-nutritive factors and plant proteins that have a more desirable amino acid composition (e.g. a higher lysine content than the non-transgenic plant). The GOI may even code for an enzyme that can be used in food processing such as chymosin, thaumatin and alpha-galactosidase. Preferably the GOI is a gene encoding for any one of a pest toxin, an antisense transcript such as that for patatin or alpha-amylase, ADP-glucose pyrophosphorylase (e.g. see EP-A-0455316), a protease antisense or a glucanase.
The term 'organism' in relation to the present invention includes any organism wherein the promoter can be activated. Preferably the organism is an amylase (e.g. alpha-amylase) producing organism such as plants, algae, fungi and bacteria, as well as cell lines thereof. Preferably the term means a plant or cell thereof, preferably a dicot, more preferably a potato. The term 'transgenic organism' in relation to the present invention means an organism comprising either an expressable construct according to the present invention or a product of such a construct. For example the transgenic organism can comprise an exogenous nucleotide sequence (e.g. GOI as herein described) under the control of a promoter according to the present invention; or a native nucleotide sequence under the control of a partially inactivated (e.g. truncated) promoter according to the present invention.
The terms "cell", "tissue" and "organ" include cell, tissue and organ per se and when within an organism. For one class/type of promoters according to the present invention the term preferably means a potato stem cell, tissue or organ and a potato sprout cell, tissue or organ for another class/type of promoters according to the present invention it preferably means potato sprout cell, tissue or organ or potato stem cell, tissue or organ.
Preferably the expressable construct is incorporated in the genome of the organism. The term incorporated preferably covers stable incorporation into the genome.
The term 'nucleotide' in relation to the GOI includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA.
The term "expression vector" means a construct capable of in vivo or in vitro expression.
The term "transformation vector" means a construct capable of being transferred from one species to another - such as from an E.Coli plasmid to a plant cell, or from agrobacterium to a plant cell. Even though the promoters of the present invention are not disclosed in EP-B-0470145 and CA-A-2006454, those two documents do provide some useful background commentary on the types of techniques that may be employed to put the present invention into practice. Some of these background teachings are now included in the following commentary.
The basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material. Several techniques exist for inserting the genetic information, the two main principles being direct introduction of the genetic information and introduction of the genetic information by use of a vector system. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27).
Thus, in one aspect, the present invention relates to a vector system which carries a promoter or construct according to the present invention and which is capable of introducing the promoter or construct into the genome of a plant such as a plant of the family Solanaceae, in particular of the genus Solanum, especially Solanum tuberosum. The vector system may comprise one vector, but comprises preferably two vectors; in the case of two vectors, the vector system is normally referred to as a binary vector system. Binary vector systems are described in further detail in Gynheung An et al. (1980), Binary Vectors, Plant Molecular Biology Manual A3, 1-19.
One extensively employed system for transformation of plant cells with a given promoter or construct is based on the use of a Ti plasmid from Agrobacterium tumefaciens or a Ri plasmid from Agrobacterium rhizogenes An et al. (1986), Plant Physiol. 81, 301-305 and Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds.: D.S. Ingrams and J.P. Helgeson, 203-208.
Several different Ti and Ri plasmids have been constructed which are suitable for the construction of the plant or plant cell constructs described above. A non-limiting example of such a Ti plasmid is pGV3850.
The promoter or construct of the present invention should preferably be inserted into the Ti-plasmid between the terminal sequences of the T-DNA or adjacent a T-DNA sequence so as to avoid disruption of the sequences immediately surrounding the T-DNA borders, as at least one of these regions appear to be essential for insertion of modified T-DNA into the plant genome. As will be understood from the above explanation, the vector system of the present invention is preferably one which contains the sequences necessary to infect a plant (e.g. the vir region) and at least one border part of a T-DNA sequence, the border part being located on the same vector as the genetic construct. Furthermore, the vector system is preferably an Agrobacterium tumefaciens Ti-plasmid or an Agrobacterium rhizogenes Ri-plasmid or a derivative thereof, as these plasmids are well-known and widely employed in the construction of transgenic plants, many vector systems exist which are based on these plasmids or derivatives thereof.
In the construction of a transgenic plant the promoter or construct may be first constructed in a microorganism in which the vector can replicate and which is easy to manipulate before insertion into the plant. An example of a useful microorganism is E. coli, but other microorganisms having the above properties may be used. When a vector of a vector system as defined above has been constructed in E. coli, it is transferred, if necessary, into a suitable Agrobacterium strain, e.g. Agrobacterium tumefaciens. The Ti-plasmid harbouring the promoter or construct of the invention is thus preferably transferred into a suitable Agrobacterium strain, e.g. A. tumefaciens, so as to obtain an Agrobacterium cell harbouring the promoter or construct of the invention, which DNA is subsequently transferred into the plant cell to be modified. Direct infection of plant tissues by Agrobacterium is a simple technique which has been widely employed and which is described in Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds.: D.S. Ingrams and J.P. Helgeson, 203-208. See also Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27).
As reported in CA-A-2006454, a large amount of cloning vectors are available which contain a replication system in E. coli and a marker which allows a selection of the transformed cells. The vectors contain for example pBR 332, pUC series, M13 mp series, pACYC 184 etc. In such a way, the construct or promoter can be introduced into a suitable restriction position in the vector. The contained plasmid is used for the transformation in E.coli. The E.coli cells are cultivated in a suitable nutrient medium and then harvested and lysed. The plasmid is then recovered. As a method of analysis there is generally used a sequence analysis, a restriction analysis, electrophoresis and further biochemical-molecular biological methods. After each manipulation, the used DNA sequence can be restricted and connected with the next DNA sequence. Each sequence can be cloned in the same or different plasmid. After each introduction method of the desired promoter or construct in the plants further DNA sequences may be necessary. If for example for the transformation, the Ti- or Ri-plasmid of the plant cells is used, at least the right boundary and often however the right and the left boundary of the Ti- and Ri-plasmid T-DNA, as flanking areas of the introduced genes, can be connected. The use of T-DNA for the transformation of plant cells is being intensively studied and is well described in EP 120 516; Hockcma, in: The Binary Plant Vector System Offset-drukkerij Kanters B.B., Alblasserdam, 1985, Chapter V; Fraley, et al., Crit. Rev. Plant Sci., 4:1-46 and An et al., EMBO J. (1985) 4:277-284.
Direct infection of plant tissues by Agrobacterium is another simple technique which may be employed. Typically, a plant to be infected is wounded, e.g. by cutting the plant with a razor or puncturing the plant with a needle or rubbing the plant with an abrasive. The wound is then inoculated with the infection of a plant may be done on a certain part or tissue of the plant, i.e. on a part of a leaf, a root, a stem or another part of the plant. The inoculated plant or plant part is then grown on a suitable culture medium and allowed to develop into mature plants.
When plant cells are constructed, these cells may be grown and maintained in accordance with well-known tissue culturing methods such as by culturing the cells in a suitable culture medium supplied with the necessary growth factors such as amino acids, plant hormones, vitamins, etc. Regeneration of the transformed cells into genetically modified plants may be accomplished using known methods for the regeneration of plants from cell or tissue cultures, for example by selecting transformed shoots using an antibiotic and by subculturing the shoots on a medium containing the appropriate nutrients, plant hormones, etc.
In summation therefore the present invention therefore relates to a promoter and, also to a construct comprising the same.
In particular the present invention relates to the use of a promoter for the expression of a GOI in an cell/tissue/organ/ organism such as one or more specific tissues of a plant, in particular a dicot plant such as a potato.
More in particular, in a preferred embodiment, the present invention relates to a partially inactivated (such as truncated) type 1 α-amylase promoter.
The present invention also relates to the application of one class of partially inactivated gene promoters to express a GOI specifically in at least the stem or sprout tissue of a dicot - especially a potato plant.
The following sample has been deposited in accordance with the Budapest Treaty at the recognised depositary The National Collections of Industrial and Marine Bacteria Limited (NCIMB) at 23 St Machar Drive, Aberdeen, Scotland, AB2 IRY, United Kingdom, on 26 August 1994:
DH5alpha-gPAmy 637 (Deposit number NCIMB 40683) This deposited sample is an E. Coli bacterial stock containing the plasmid pBluescript (see Figure 6 for general map thereof) containing the promoter of SEQ. I.D. No. 1 - i.e. the Amy 1 promoter. Details on how the plasmid was formed are given later.
The present invention will now be described only by way of examples, in which reference shall be made to the following Figures, in which:
Figure 1 shows Southern blots for restiction enzyme digests of a clone according to the present invention (Figures 1A and 1B);
Figure 2 shows a restriction map of a clone according to the present invention; Figure 3 is a sequence map of a clone according to the present invention;
Figure 4 is the nucleotide sequence of a promoter according to the present invention; Figure 5 shows the primer sequences for use in the present invention; and
Figure 6 is a plasmid map of pBlueScript KS- (2.96 kb).
In slightly more detail, Figures 1A and 1B are gel patterns of digested DNA of the lamda 637 clone; Figure 2 is a map of the clone lambda 637 and subclones, wherein the darkened boxes are the coding sequences, the empty boxes are the promoter sequences, --- = not sequenced, the shaded boxes represent intron sequences and the shaded and striped boxes represent the transit and leader peptide coding regions; Figure 3 is the sequence map of B2-7 and the individual primers used are indicated above the arrow and correspond to the list given in Figure 5, the arrows show the direction and extent of the individual sequence reactions, the position of the structural gene is shown at the bottom, and E=EcoRI, H=HindIII and B=BamHI; in Figure 4 is the nucleotide sequence of the alpha-amylase promoter sequence and the suggested CAP sites, CCAAT boxes and TATA boxes are underlined; in Figure 5 Uni=T7 primer and Rev = T3 primer.
MATERIALS AND METHODS
Plant material Root tissue were harvested from flowering potato (Solanum tuberosum, cv. Satuma) plants. The roots were sliced directly into liquid nitrogen and 10-15g portions were stored at -80°C until use. Bacterial strains
Figure imgf000016_0001
Phages and plasmids
Figure imgf000016_0002
Media and plates
L- Broth (LB) medium:
Per litre, 5g of yeast extract, 5g of NZ-amide, 5g of NaCl, 5g of bacto-peptone. Autoclave.
LB-plates:
LB medium plus 15g Bacto agar per litre. Autoclave. Pour into plastic petri dishes (25 ml/dish).
Amp-plates:
As LB-plates plus 35 mg ampicillin per litre after autoclaving. AXI-plates:
As LB-plates plus 35 mg ampicillin, 120 mg IPTG (isopropylthiogalactoside), 40mg Xgal
(dissolved in dimethylformamide) per litre after autoclaving. [Xgal:
5-bromo-4chloro-3indolyle-β-D-galactoside.]
Water:
The water used in Materials and Methods was always distilled and autoclaved before use.
Isolation of high MW genomic potato DNA
In order to gain high molecular weight genomic DNA a procedure essentially as described by Fischer and Goldberg (6), was followed. This include first isolation of nuclei followed by preparation of the nuclear DNA. 10-15g Satuma root tissue were ground to a fine powder in liquid nitrogen and homogenized in 100 ml H buffer (1×H buffer(1l): 100ml 10×HB, 250ml 2M sucrose, 10 ml 100mM PMSF, 1ml β-mercaptoethanol, 5 ml Triton X-100, 634ml H2O. Adjust to pH 9.5. Add β-mercaptoethenol just before use. 10×HB: 40mM spermidine, 10mM spermine, 0.1mM Na2-EDTA, 0.1mM Tris, 0.8mM KCl, adjusted to pH 9.4-9.5 with 10N NaOH. PMSF: phenylmethylsulfonyl fluoride dissolved in ethanol).
The resuspended plant material was filtered through a 70μm nylon filter (Nitex filter, prewetted in 1xH buffer). The resulting filtrate was poured into two centrifuge bottles (Sorvall GSA) and the nuclei pelleted at 4000 r.p.m for 20 min at 4°C. The supernatant was discarded and the pellets were gently resuspended by adding 20 ml 1×H buffer per tube and then swirling the tubes carefully. The nuclei were pelleted again at 4000 r.p.m. for 20 min at 4°C, the supernatant removed and the pellets resuspended gently in 10 ml 1×H buffer. The supernatant was pooled and 20 ml cold lysis buffer (lysis buffer: 2% Sarcosyl, 0.1M Tris, 0.04M Na2-EDTA) was added dropwise while the solution was stirred gently. Immediately after the last drop of lysis buffer was added, 0.972g CsCl/ml solution was stirred gently into the solution (the solution should now be at room temperature). The resulting solution was centrifuged for 45 min at 10 krpm, 4°C. The supematants were carefully removed using a pasteur pipet avoiding any protein debris floating on the top or disturbing the pellets. The volume of the supematants were determined and 0.2 mg ethidium bromide/ml was added.
The DNA solution was then gently poured into quickseal polyallomer tubes, which were then sealed. The tubes were centrifuged in a Beckman VTI 65 rotor at 18°C and 40 k r.p.m. for 38 h.The genomic band was removed under UV-light with a 15-18 gauge needle attached to a 5-ml syringe and poured gently into a 5 ml polyallomer tube. The tube(s) was filled with a 1.57 g/ml CsCl solution in 50mM Tris-Hcl(pH 9.5), 20 mM Na2-EDTA. 75 μl ethidium bromide (5mg/ml) was added/tube. The tubes were centrifuged in the VTI 65 rotor at 18°C and 46 krpm for 17 h. The genomic band was removed under long-wave UV light and the ethidium bromide was extracted with CsCl-saturated isopropanol (7 to 8 times). The CsCl was removed from the DNA by dialysis in TE-buffer (1×TE: 10 mM Tris-HCl, 1 mM Na2-EDTA pH 8.0) at 4°C for 18 h with three changes. The high MW genomic potato DNA was not further precipitated and was kept at 4°C.
Construction of a potato genomic library
High MW genomic potato DNA was prepared from cv Satuma roots as decribed above. The quality of the DNA was tested by restriction enzyme digestion and gel electrophoresis.
The genomic DNA was partially digested with Sau3A and the created fragments (9-23 kb) were inserted into the BamHI site of the λ EMBL3 vector (4). Approximately 1.1×106 independent isolates were plated and amplified to form a permanent library (7).
Plaque hybridization was used to screen the library for α-amylase genes. Screening of the library
Screening of the potato genomic library was carried out essentially as described by (8,9). The pfu/ml (pfu:plaque forming unit) of the amplified genomic library was determined in duplicate prior to the screening. Infection competent cells (PKL17 or LE392) were prepared by inoculating the cells in 30 ml fresh L-Broth containing 0.2% sucrose and 10 mM CaCl2. The cells were cultivated for 4-5 h at 37°C before 0.1 vol of cold CaCl2 was added and kept on ice until use. 100 μl phages diluted in phagebuffer to give an appropriate number of pfu (1×phagebuffcr: 10 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 20 mM NaCl) were mixed with 25-100 μl freshly made cells (dependent on the actual number of cells) and incubated at 37°C for 15-20 min. The suspension was mixed with 3 ml warm (42°C) 0.8-1% top agar containing 10 mM MgCl2 and plated out on dry LB plates. LB plates of 22×22cm (dried for 3-4 h at 37°C) were used for screening of the genomic library. Each plate contained approximately 2×105 plaques, which were mixed with 1 ml of infection competent cells (prepared as above) and incubated for 20 min at 37°C. This mixture was then added to a 25 ml of warm (42-45°C) 0.3% top agarose with 10 mM MgCl2 and the solution was poured onto a fresh dry LB plate. The large LB plates were incubated (not upside down) overnight at 37°C. Phages from the plaques were transferred to Hybond N filters (Amersham) in duplicates. The plates were placed at 4°C for 1 to 2 h to prevent the agarose layer from sticking to the filters. The plates were placed on ice, just before use and they remained on the ice when working with the filters.Two Hybond N filters and a plate were marked for orientation of the filters .
The first filter was laid on the plaques for 45 sec; then floated on denaturation buffer (0.5 M NaOH, 1.5 M NaCl) for 7 min, with the phages facing up, then floated on neutralization buffer (0.5 M Tris-HCl (pH 7.4), 3 M NaCl) for 2 times 3 min and finally washed in 2×SSC (1×SSC: 0.15 M NaCl, 0.015 Na-citrate). The filter was air dried and the phage DNA was fixed to the membrane by UV crosslinking. The second filter was laid on the same plate, after the first, for 120 sec and then treated as the first. These filters were used in plaque hybridization following the Hybond N membrane protocol according to suppliers (Amersham) instructions. X-ray film from both the first and second Hybond N membrane was orientated so that the signals from both filters fitted each other.
The positive plaques were cut with a scalpel (1×1 cm blocks) and submerged in 1 ml phage buffer.
The phage containing tubes were stored airtight (parafilm) at 4°C after 2-3 drops of chloroform has been added. The plaque containing plates (22×22 cm) were stored by placing a piece of soaked (chloroform) filterpaper in the lid. The plates were also stored airtight at 4°C with the plaques facing up. Further purification of the positive plaques were done by plating dilutions of the stock tube (containing the 1×1 cm block) with freshly prepared cells and plate them on round LB plates with 1% warm (42°C) top-agar and 10 mM MgCl2. New filter prints were made with Hybond N following the procedure outlined above with the 22×22 cm plates. Plaques which gave positive signal were isolated by sticking the tip of a pasteur pipette though the plate and transfer it to 500 μl phagebuffer. New series of dilutions were made, plated and the respective filters hybridized until the positive plaques were purified. The phages were stored airtight, at 4°C either in the 500 μl phagebuffer with 1 drop of chloroform, or as phages isolated from a plate lysate.
The plate lysate stock was made as decribed by (9).
Isolation of recombinant λ DNA
Large-scale preparations followed the method decribed in (14), which included binding the recombinant phage DNA on a CsCl gradient. Two versions (A,B) of a small-scale preparation were used as follows: A) LE392 cells were inoculated in LB with 0.2% maltose and 10 mM MgCl2 and grown O/N at 37°C. The cells were pelleted by centrifugation for 10 min, at 4°C in a Sorvall centrifuge, and resuspended gently in 1 volume of cold 10 mM MgSO4. The cells were stored at 4°C until use. Five single plaques from a plate were transferred to 500 μl phagebuffer and allowed to stand for 2-2½ h at 4°C.
After votex of the tube 100 μl of the liberated phages were mixed with 200 μl freshly prepared LE392 cells. Alternatively 50-100 μl liberated phages from aplate lysate were mixed with the cells. Phages and cells were incubated for 20 min at 37°C and then added to a prewarmed (37°C) 25 ml LB with 20 mM MgSO4 and 30 mM Tris-HCl pH 7.5 and incubated, shaking O/N at 37°C. A further 10 ml prewarmed LB with 20 mM MgCl2 and
30 mM Tris-HCl pH 7.5 was added and the mix incubated for 1-2 h shaking at 37°C. After clear lysis (eventuel a few drops of chloroform was added to help) and the solution was centrifuged at 8000 r.p.m. for 10 min at 4°C. The supernatant was transferred to a new tube and centrifuged again if necessary to remove cell debris. The recombinant λ DNA was then purified using a Qiagen column following the suppliers instructions (10). B) The procedure was as under A) until after the first centrifugation of the O/N culture. The supernatant was transferred to a new tube and DNase was added corresponding to 1 μg/ml.
The solution was incubated 30 min at 37°C and then 1 volume of cold 20% PEG, 2 M NaCl mixed in phagebuffer was added and the mixture was incubated 1 h on ice. The phages were pelleted by centrifugation for 20 min, 4°C at 10 krpm. The PEG pellet was resuspended in 400 μl phagebuffer and transferred to an eppendorf tube. 1 μl of RNase (10 mg/ml) is added and the tube incubated for 30 min at 37°C. Then 8 μl 0.25 M Na2-EDTA, pH 8.0 and 4 μl 10% SDS was added, the tube was incubated a further 15 min at 68°C.
The mixture was allowed to gain room temperature and then an equal phenol saturated with TE-buffer (1×TE: 10 mM Tris pH 7.5, 1 mM Na2-EDTA) was used to extract the DNA. A equal mixture of saturated phenol-chloroform was used to extract the upper aqueous phase and a final chloroform extraction was done. The upper phase was transferred to a new tube and the solution was made 0.3 M Na-acetate and 2-3 vol cold ethanol was added. The precipitation of the DNA was accomplished by storing at O/N at -20°C, centrifuging for 5 min and resuspend the pellet in 50-100 μl TE-buffer. The amount and quality of the recombinant phage DNA was tested by restrictions enzyme digest and agarose (0.8-1%) gel electrophoresis (11).
Preparation of plasmid DNA
The plasmid preparation was as described in EP-B-0470145. In particular, small scale preparation of plasmid DNA was performed as follows.
Bacterial strains harbouring the plasmids were grown overnight in 2 ml L-Broth (LB) medium with ampicillin added (35 μg/ml). The operations were performed in 1.5 ml Eppendorf tubes and centrifugation was carried out in an Eppendorf centrifuge at 4°C. The cells from the overnight culture were harvested by centrifugation for 2 min., washed with 1 ml 10 mM Tris-HCl (pH 8.5), 50 mM EDTA and centrifuged for 2 min. The pellet was suspended in 150 μl of 15% sucrose, 50 mM Tris-HCl (pH 8.5), 50 mM EDTA by vortexing. 50 μl of 4 mg/ml lysozyme was added and the mixture was incubated for 30 min. at room temperature and 30 min. on ice. 400 μl ice cold H2O was added and the mixture was kept on ice for 5 min, incubated at 70-72°C for 15 min. and centrifuged for 15 min.
To the supernatant was then added 75 μl 5.0 M Na-perchlorate and 200 μl isopropanol (the isopropanol was stored at room temperature), and the mixture was centrifuged for 15 min. at 4°C. The pellet was suspended in 300 μl 0.3 M Na-acetate and 2-3 vol. cold ethanol was added.
Precipitation was accomplished by storing at either 5 min. at -80°C or O/N at -20°C, centrifuging for 5 min., drying by vacuum for 2 min. and redissolving the pellet in 20 μl H2O. The yield was 5-10 μg plasmid DNA. Large scale preparation of plasmid DNA was accomplished by simply scaling up the small scale preparation ten times. Working in 15 ml corcx tubes, all the ingredients were scaled up ten times. The centrifugation was carried out in a Sorvall cooling centrifuge at 4°C. Only changes from the above will be mentioned in the following. After incubation at 70-72°C, the centrifugation was for 30 min. at 17,000 rpm. After adding isopropanol and after adding cold ethanol, the centrifugation was for 15 min. at 17,000 rpm.
The final plasmid DNA pellet was then suspended in H2O and transferred to an Eppendorf tube and then given a short spin to remove debris. The supernatant was adjusted to 0.3 M Na-acetate and 2-3 vol. cold ethanol were added. The pellet was resuspended in 40 μl H2O. The yield was usually 20-28 μg plasmid DNA.
To obtain very pure plasmid DNA, 200-300 μg of isolated plasmid DNA from the upscaled method were banded on a CsCl gradient. Solid CsCl was mixed with H2O (1:1 w/v) and 0.2 mg/ml ethidium bromide was added. The solution was poured into a quick-seal polyallomer tube and the plasmid DNA, mixed with solid CsCl (1:1 w/v). The tube was filled, sealed and centrifuged in a Beckman VTI 65 rotor at 15°C, 48,000 rpm for 16-18 hours. The centrifuge was stopped by without using the brake. The banded plasmid DNA was withdrawn from the tubes using a syringe and the ethidium bromide was extracted with CsCl-saturated isopropanol 7-8 times. The CsCl was removed by dialysis in 10 mM Tris-HCl (pH 8.0), 1 mM EDTA for 48 hours with three changes of buffer. The DNA was precipitated by adjusting to 0.3 M Na-acetate and adding 2-3 vol. cold ethanol. The small scale plasmid preparation from E. coli was usually followed by a LiCl precipitation to remove RNA from the DNA solution. The small scale prepared plasmid DNA was dissolved in 100 μl destilled water. 1 vol of 5M LiCl was added and the mixture incubated at -20°C for 30 min followed by centrifugation at 12,000 rpm. for 15 min, 4°C. The supernatant was transferred to a new eppendorf tube and 2 vol TE buffer or water was added. Precipitation with 2.5 vol of 96% ethanol was accomplished by storing either 10 min. at -80°C, or O/N at -20°C. The DNA was precipitated by centrifuging for 15 min. 12,000 rpm ,at 4°C, drying by vacuum for 2 min and redissolving in 18 μl of TE or water.
Restriction enzyme digestion
The protocol followed was that outlined in EP-B-0470145. In particular, all restriction endonucleases were from Biolabs , Amersham or Boehringer Mannheim and were used according to the supplier's instructions. 1 unit of enzyme was used to 1 μg of DNA and incubation was for 2 hours. The buffer was changed in double digestions, by changing the volume or by adding the necessary ingredient according to the enzyme instructions.
Labelling of DNA
A random primed DNA labelling kit (Boehringer Mannheim) was used according to the suppliers instructions. Briefly, 2μl DNA fragment (25-50 ng) is mixed with 8μl H2O and incubated at 95°C for 10 min to denature the DNA. Spin shortly and place on ice. Then add 1 μl dGTP, dATP and dTTP of each, 2 μl reactionsmix and 5 μl (approx. 50 μCi dCTP32). 1 μl Klenow enzyme starts the reaction and the tube is incubated at 37°C for 30 min. Then place on ice. The labelled DNA fragment was purified using an ELUTIP column (Schleicher & Schuell). The column was prepared by prerunning (gravity) it with 3 ml high salt buffer (1.0 M NaCl, 20 mM Tris-HCl (pH 7,5), 1.0 mM EDTA), followed by 5 ml low salt buffer (0.2 M NaCl, 20 mM Tris-HCl (pH 7,5), 1.0 mM EDTA). 250 μl low salt was added to the labelling tube and the entire solution was laid on the prepared column. Then the column was washed with 2x400 μl low salt followed by 3×200 μl high salt. The eluted radioactive probe was then heat denatured and used in hybridization.
Southern transfer and Hybridization
The DNA fragments to be transferred were fractionated on non-denaturing agarose gels (109) and transferred to either Hybond™ N or Hybond™ N+, positively charged nylon membrane (Amersham Life Science) by Southern blotting (12,13). Hybridization to the Hybond™ N nylon membranes was followed according to the supplier's instructions (13).
Preparation of vectors
The preparation of vectors was as decribed in EP-B-0470145 as follows: Vectors (pBS-/+ or pBSK-/+) were digested with one or two restriction enzymes, extracted twice with saturated phenol (the phenol was first mixed with 0.1 M Tris-HCl, then mixed twice with TE-buffer (10 mM Tris-HCl, pH 8, 1 mM Na2-EDTA)) and once with chloroform and precipitated with 0.3 M Na-acetate and 2.5 vol cold ethanol. The pellet was rinsed in 70% cold ethanol and dissolved in H2O, giving a concentration of 25-50 ng/μl. The vectors were tested for background before use (sclf-ligation with and without T4-DNA-ligase). If necessary the vector was treated with Alkaline phosphatase (Boehringer Mannheim) as described by the supplier. After such a treatment the resulting pellet was resuspended in H2O to give a final concentration of 10 ng/μl.
Ligation
The phage DNA or plasmid comprising a fragment to be subcloned was digested with one or more restriction enzymes and run in either a 5% aerylamide gel or an appropriate agarose gel. The fragment to be subcloned was isolated from the gel either by electroelution as decribed in (109) or using a GENECLEAN II Kit (BIO 101 Inc., La Jolla, California) following the suppliers instructions. Various ratios of fragment to vector were used (from 2:1 to 5:1, based on the number of molecules) in the ligation reaction. 1 μl (10-100 ng) of a solution containing the vector was combined with the fragment, 1 μl of T4-ligation buffer (10×(20 mM Tris-HCl, pH 7.6, 10 mM MgCl2, 0.6 mM ATP, 10 mM dithiotheitol)) and 1 μl of T4-DNA ligase (Boehringer Mannheim) were added to a mixture of fragment and vector to a total volume of 10 μl. The reaction was incubated at 15°C O/N if the ligated DNA fragments had sticky ends. If the DNA had blunt ends, the incubation was at room temperature for 1 hour. The ligation mixture was stored at -20°C if not used immediately, usually 5 μl of the ligation mix was used for transformation.
Preparation of competent E. coli cells and transformation This was done according to the protocols laid down in EP-B-0470145 as follows:
JM109 cells (or DH5α) were inoculated in 4 ml L-Broth made to 10 mM MgSO4 and 10 mM MgCl2. The cells were grown O/N at 37°C. 1 ml of the O/N culture was added to 40 ml prewarmed (37°C) LB medium (with 10 mM MgSO4 and 10 mM MgCl2). The culture was shaken at 250-275 rpm for 1 to 2 h until the OD450 reached 0.8-0.9. The cells were harvested by centrifugation at 5000 rpm for 10 min at 4°C. The pellet was gently resuspended in 30 ml of cold 0.1 M CaCl2, another centrifugation pelleted the cells again and they were then resuspended in 15 ml of cold 0.1 M CaCl2. The suspension was placed on ice for 20 min followed by a centrifugation as before. Finally, the cells were gently resuspended in 3 ml of cold 0.1 M CaCl2 and placed on ice for at least 1 h before they were ready to use for transformation (14).
5 μl of ligation mix was combined with 95 μl of cold sterile TCM (10 mM Tris-HCl, pH 7.5, 10 mM CaCl2, 10 mM MgCl2, and 0.2 ml of the competent cells.
The mixture was allowed to stand for at least 40 min on ice, then 5 min at 37°C (or 2 min at 42°C). The solution was transferred to 0.8 ml of L-Broth, 10 mM MgSO4, 10 mM MgCl2, and incubated for 45 min at 37°C and then plated out on 5 AXI or other plates (as e.g. Amp-plates) at 0.2 ml/plate. The plates were allowed to stand 10 min before being inverted and incubated O/N at 37°C.
They were then stored in plastic bags upside down at 4°C. Purification of primers following synthesis on a DNA Synthesizer
The primer was synthesized on a polystyrene support column (Applied Biosystems, 393 DNA/RNA Synthesizer) and was eluted from the column with NH4OH. The column was broken open and 1.5 ml NH4OH was added to the polystyrene material in a small glass tube. The mixture was incubated at 85°C for 1 hour followed by 5 min on ice. The supernatant containing the single stranded DNA was transferred to eppendorf tubes, and the NH4OH was evaporated in a vacuum centrifuge for at least 3 h.Pellet was resuspended in 200 μl destilled water and precipitated with 550 μl ethanol and 20 μl sodium acetate. The pellet was resuspended in 200 μl water and precipitation with ethanol and sodium acetate was repeated. Finally the pellet was resuspended in 100 - 200 μl destilled water and the OD260nm was measured by a Gene Quant RNA/DNA calculator (Pharmacia) of single stranded DNA is calculated. An OD260nm of 1 corresponds approx. to 33 μg/ml single stranded DNA.
Subcloning and sequencing
Purified λ DNA was digested with appropiate restrictions enzymes and the generated fragments were isolated from agarose gels using a GeneClean Kit (BIO 1 Inc., La Jolla, California) according to the suppliers instructions.
Genomic DNA fragments (or fragments obtained from plasmids) were ligated into the polylinker region of the BlueScribe vector pBS-/+ (or pBSK-/+, Stratagene). After transforming an E. coli strain with the ligated plasmid the recombinant subclones could be selected by plating on AXI plates (they will be white and the nonrecombinant clones will be blue when the vector is a pBlueScribe plasmid,(5)).
Plasmid DNA from putative subclones were digested with appropiate restriction enzymes, subjected to gelelctrophoresis and after Soutern blotting, hybridized with an appropiate labelled DNA probe, to verify the origin of the inserted fragment.
The generated pBS genomic DNA subclones were then sequenced according to the plasmid preparation protocol outlined in EP-B-0470145. In this regard, the plasmid (double stranded template) to be sequenced was purified by the plasmid small scale preparation method. The DNA was denatured in 0.2 M NaOH (5 min at room temperature) the mixture was neutralised by adding 0.4 vol of 5 M ammonium acetate (pH 7.5) and then precipitated with 4 vol. of cold ethanol (5 min at -80°C). The pellet was rinsed with 70°C cold ethanol and resuspended in 10 μl H2O.
Sequencing was accomplished with a Sequenase™ DNA Sequencing Kit from United States Biochemical Corp., following the sequencing Protocol enclosed in the kit (Sequenase™ :Step by Step Protocols for DNA sequencing with Sequenase, 3rd Edition, United States Biochemical Corporation PO Box 22400 Cleveland Ohio 44122).
The following modifications were however made to the suggested protocol. Instead of adding DTT, Labelling mix and 35SdATP to the annealed DNA mix, 4 ml of 35Sequetide (DuPont) was added.
In addition to T3 and T7 primers (Stratagene) a whole range of other primers generated on a DNA synthesizer (Applied Biosystems, 392 DNA/RNA Synthesizer) were used. 0.5 pmol of primer was used to sequence 1 pmol of plasmid. The primer sequences are shown in the attached Figure 5. The sequencing reactions were subjected to electrophoresis on 6 % or 8 % denaturing polyacrylamide gels for 1 to 4 hours at 40 W, then dried by a gel drier and autoradiographed for 3-48 hours at room temperature. The denaturing sequencing gels were made from pre-mixed polyacrylamide solutions , Gel-Mix 6 and Gel-Mix 8 (GIBCO BRL, Life technologies, Inc) according to the manufacturers instructions.
Isolation of α-amylase genomic clones
Several cDNA clones encoding α-amylase from potato (Solanum tuberosum) had previously been isolated (described in EP-B-0470145). The plasmid pAmyZ6 (EP-B-0470145) encoding a partial α-amylase was digested with ClaI and SmaI. This creates two fragments of approx. 500 bp covering the α-amylase coding sequence and untranslated 3'end. Both fragments were used as probes (see "DNA labelling" in Materials and Methods) to screen the genomic poatato λ DNA library (see "construction of a potato genomic library" in Materials and Methods). Screening of approx. 1.6×106 phages were carried out as decribed in Materials and Methods. Twenty four positive plaques were isolated and λ DNA (see "Materials and Methods") was made from 8 of them. A SalI digest (release the inserted genomic fragment from the λ arms) showed that the 8 clones contain genomic fragments ranging from approx 10.5 kb to 13.5 kb in size.
The clone gPAmy637 was chosen for further analysis by Southern blotting and hybridizations.
The α-amylase clones pAmyZ6 and pAmyZ1 (see EP-B-0470145 for a detailed description) contain sequences encoding an α-amy 1 type of α-amylase. They are however, not identical and using both for hybridizations to Southern blots which contain EcoRI, HindIII and BamHI digests of the gPAmy637 clone, revealed a slightly different hybridization pattern between them (sec Figure 1A and 1B). Prominent hybridizing bands, (called B1 and B2 in the BamHI digested lane, H1 and H2 in the HindIII digested lane and, E1 and E2 in the EcoRI digested lane, Figure 1) from all three digests of gPAmy637 were subcloned into pBS and pBSK vectors predigested with appropiate enzymes. Plasmid DNA isolated from transformed E.coli cells (see Material and Methods) were digested with appropiate restriction ezymes and used for Southern analysis using the insert of pAmyZ6 (it was cut out of the pBSK plasmid using AccI and SacI) as probe, to verify their origin. A BamHI map of the gPAmy637 λ clone is shown in Figure 2. This map covers approx. 2/3 of the genomic DNA insert in the clone (insert size approx. 13.5 kb). Using various fragments of the gPAmyZ6 and the gPAmyZ1 cDNA clones (5' and 3" fragments) as probes to Southern blots of digests of both gPAmy637 and another λ clone gPAmy651, it was possible to map more than one gene encoding the α-amy 1 type α-amylase. The position of both an α-amy 1 type gene, corresponding to the pAmyZ1 cDNA clone and another α-amy 1 type pseudogene, corresponding to the pAmyZ6 cDNA clone are shown in Figure 2. Sequencing covering most of this region of the gPAmy637 λ clone verified the identity of the genes. The sequenced region included the B1 (partially) and B2 subclones (B1:B1-5 and B2:B2-7) and in addition the H1 and H2 subclones (HLH1-H and H2:H2-J) see figure 2 for their mapping positions.
Subcloninp a genomic fragment containing an a-amvlase promoter from potato
The B2-7 genomic fragment (see Figures 1 and 2) of 3763 bp was subcloned from gPAmy637 into a dephosphorylated BamHI site of a pBKS- vector (see Materials and Methods). This subclone contains the ATG initiation codon, 1669 bp downstream of it covering approx. half of the structural gene and 2094 bp upstream covering the promoter region of the α-amy 1 type α-amylase gene. As shown by others (e.g. see 15-22) the sequence region upstream of the ATG initiation codon covering about 1000-1500 bp include the entire promoter, enough to mediate transcription of the gene at the right time and place.
Sequence of an a-amylase promoter
The sequence of the BamHI subclone (B2-7) isolated from gPAmy637 was determined (see Materials and Methods). This covers in total 3763 bp and the sequence map is shown in figure 3. The individual primer used is indicated in Figure 3 and corresponds to the list given in figure 5. The DNA sequence of the 2094 bp promoter region is shown in Figure 4. The promoter sequence was compared with published sequences in the EMBL database (using a PC-gene program from IntelliGenetics, Inc., California) and no sequence with significant overall homology was found.
Putative TATA- and CAAT- boxes are underlined in Figure 4 and possible CAP sites are also indicated. Their positions correspond to the positions they are found in other eucaryotic polymerase II promoters (23-24).
An expression analysis of the α-amylase gene of the present invention revealed that the α-amylase type 1 gene(s) is weakly expressed in potato sprouts. However, it is more strongly expressed in potato stems. This type is not found in leaves, tuber or root tissues.
In summation, the applicability of the promoters of the present invention is widespread. With the promoters it is possible to direct the expression of proteins into different tissues in the potato plant. It would also be possible to direct the expression of proteins into different tissues in other dicot plants.
Other modifications of the present invention will be apparent to those skilled in the art without departing from the scope of the invention.
REFERENCES
I. Yanisch-Perron, C, Vieira, J., Messing, J. (1985) Gene 33:103-119 2. Brock, K., Beggs, J.D., Brammar, W.J., Hopkins, A.S. and Murray, N.E. (1976) Mol Gen Genet 146:199
3. Murray, N.E., Brammar, W.J. and Murray, K. (1977) Mol Gen Genet 150: 53 4. Frischauf A-M., Lehrach H., Poustka A., and Murray N. (1983) J Mol Biol 170, 827-842
105. Short, J.M., Fernandez, J.M., Sorge, J.A. and Huse, W.D. (1988) Nucleic Acids Res 16, 7583-7600
6. Fischer, R.L. and Goldberg, R.B. (1982) Cell 29: 651
7. Stratagene cloning system, Custom library, 11099 North Torrey Pines Road, -La Jolla, California 92037
8. Benton, W.D. and Davis, R.N. (1977) Science 196, 180-182
9. Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular cloning: A laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press
10. The Qiagenologist. Application Protocol. 2nd Edition. Qiagen.
11. Maniatis, T. et al. (1982) Molecular Cloning A Laboratory Manual. Cold Spring Harbour Laboratory Press
12. Southern, E.M. (1975) J Mol Biol 98: 503-517 13. Amersham Life Science protocol: HybondTM-N (N+; positively charged nylon membrane) Version 2.0.
14. Mandell, W and Higa, A. (1970), J Mol Biol 166, 557-580
15. Steege, G., Nieboer, M., Swaving, J. and Tempelaar, M.J. (1992) Plant Mol Biol 20: 19-30
16. Matton, D.P., Prescott, G., Bertrand, C, Camirand, A. and Brisson, N. (1993) Plant Mol Biol 22: 279-291
17. Ohta, S., Hattori, T, Morikami, A. and Nakamura, K. (1991) Mol Gen Genet 225: 369-378 18. Ueda, T., Pichersky, E., Malik, V.S. and Cashmore, A.R. (1989) Plant Cell 1:217-227
19. Stougaard, J., Sandahl, N.N., Grøn, A., Kühle, A. and Marcker, KA. (1987) EMBO J 6: 3565-3569
20. Stougaard, J., Jørgensen, J.E., Christensen, T., Kühle, A. and Marcker, K.A. (1990) Mol Gen Genet 220, 353-360
21. Burow, M.D., Sen, P., Chlan, C.A. and Murai, N. (1992) Plant J 2: 537-548
22. Lorberth, R., Dammann, C, Ebneth, M., Amati, S. and Sanchez-Serrano, J.J. (1992) Plant J 2: 477-486
23. Bucher, P. and Trifonov, E.N. (1986) Nucl Acid Res 14, 10009-100026
24. Yamaguchi-Shinozaki, K. and Shinozaki, K. (1993) Mol Gen Genet 236: 331-340 25. Compendium of Potato Diseases (1990), cd. W.J. Hooker. APS Press, The American Phytopathological Society
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001

Claims

1. A promoter comprising the sequence shown as Seq.I.D.No. 1 or a variant, homologue or fragment thereof.
2. A promoter comprising the sequence shown as Seq.I.D.No. 1 or a variant, homologue or fragment thereof but wherein at least a part of the promoter is inactivated.
3. A promoter comprising a sequence that is a truncated version of the sequence shown as Seq.I.D.No. 1.
4. A construct comprising the promoter according to any one of claims 1 to 3 fused to a GOI.
5. An expression vector comprising the invention according to any one of claims 1 to 4.
6. A transformation vector comprising the invention according to any one of claims 1 to 5.
7. A transformed cell comprising the invention according to any one of claims 1 to 6.
8. A transgenic organism comprising the invention according to any one of claims
1 to 7.
9. A transgenic organism according to claim 8 wherein the plant is a potato plant.
10. Use of a promoter as defined in claim 1 or claim 2 or claim 3 to direct expression of a GOI in sprout or, preferably, stem cell, tissue or organ of a plant.
PCT/EP1995/002195 1994-10-21 1995-06-06 Promoter from a plant alpha-amylase gene WO1996012813A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU30750/95A AU3075095A (en) 1994-10-21 1995-06-06 Promoter from a plant alpha-amylase gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9421292A GB9421292D0 (en) 1994-10-21 1994-10-21 Promoter
GB9421292.5 1994-10-21

Publications (1)

Publication Number Publication Date
WO1996012813A1 true WO1996012813A1 (en) 1996-05-02

Family

ID=10763218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/002195 WO1996012813A1 (en) 1994-10-21 1995-06-06 Promoter from a plant alpha-amylase gene

Country Status (3)

Country Link
AU (1) AU3075095A (en)
GB (1) GB9421292D0 (en)
WO (1) WO1996012813A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063068A1 (en) * 1998-06-04 1999-12-09 The University Of Queensland Phenotype modifying genetic sequences
AU772155B2 (en) * 1998-06-04 2004-04-08 University Of Queensland, The Phenotype modifying genetic sequences

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006454A1 (en) * 1988-12-21 1990-06-21 Mario Rocha-Sosa Potatoe tuber specific transcriptional regulation
WO1990012876A1 (en) * 1989-04-24 1990-11-01 Aktieselskabet De Danske Spritfabrikker (Danisco A/S) POTATO α-AMYLASE GENES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006454A1 (en) * 1988-12-21 1990-06-21 Mario Rocha-Sosa Potatoe tuber specific transcriptional regulation
EP0375092A1 (en) * 1988-12-21 1990-06-27 Institut Für Genbiologische Forschung Berlin Gmbh Potato tuber specific transcriptional regulation
WO1990012876A1 (en) * 1989-04-24 1990-11-01 Aktieselskabet De Danske Spritfabrikker (Danisco A/S) POTATO α-AMYLASE GENES
EP0470145B1 (en) * 1989-04-24 1994-04-13 Aktieselskabet De Danske Spritfabrikker (Danisco A/S) Potato alpha-amylase gene

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
F. GUBLER AND J.V. JACOBSEN;: "Gibberellin-responsive elements in the promoter of a barley high-pI alpha-amylase gene", PLANT CELL, vol. 4, pages 1435 - 1441 *
M.-T. CHAN ET AL.;: "Novel gene expression system for plant cells based on induction of alpha-amylase promoter by carbohydrate starvation", J. BIOL. CHEM., vol. 269, pages 17635 - 17641 *
P.J. RUSHTON ET AL.;: "Aleurone nuclear proteins bind to similar elements in the promoter regions of two gibberellin-.related alpha-amylase genes", PLANT MOL. BIOL., vol. 19, pages 891 - 901 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063068A1 (en) * 1998-06-04 1999-12-09 The University Of Queensland Phenotype modifying genetic sequences
AU772155B2 (en) * 1998-06-04 2004-04-08 University Of Queensland, The Phenotype modifying genetic sequences

Also Published As

Publication number Publication date
AU3075095A (en) 1996-05-15
GB9421292D0 (en) 1994-12-07

Similar Documents

Publication Publication Date Title
US6184443B1 (en) Cold-inducible and tuber-specific promoter sequence from potato α-amylase gene
US6166292A (en) Raffinose synthetase gene, method of producing raffinose and transgenic plant
US6156956A (en) Control of fruit ripening through genetic control of ACC synthase synthesis
Suzuki et al. An Atropa belladonna hyoscyamine 6β-hydroxylase gene is differentially expressed in the root pericycle and anthers
KR100225352B1 (en) Chemically regulatable dna sequences and genes and uses thereof
JP3281512B2 (en) Methods for producing virus-resistant plants
MXPA97002881A (en) Isolated promoter of the p
AU657276B2 (en) Recombinant ACC synthase
WO1997004113A2 (en) Inhibition of gene expression
WO1990007001A1 (en) Overexpression of chitinase in transgenic plants
JP2002503081A (en) Gene expression in transgenic plants
WO1997004112A2 (en) Inhibition of gene expression
US5998701A (en) Potatoes having improved quality characteristics and methods for their production
US5994625A (en) Antifungal chitin binding proteins and DNA coding therefor
US5919998A (en) Genetic control of plant hormone levels and plant growth
CA2264567A1 (en) Antifungal proteins, dna coding therefore, and hosts incorporating same
JP3538428B2 (en) Plant promoter and gene expression method using the promoter
US5981836A (en) Plant plastid division genes
JP2001512972A (en) Sense intron inhibition of starch branching enzyme expression
WO1996012813A1 (en) Promoter from a plant alpha-amylase gene
CN114854703A (en) Flavone synthase I/flavanone-3-hydroxylase and application thereof in flavonoid compound synthesis field
CN114716522A (en) Application of KIN10 protein and related biological materials thereof in saline-alkali tolerance of plants
WO1998054334A1 (en) Cloning of udp-galactose epimerase
AU681009B2 (en) Antifungal proteins, DNA coding therefor, and hosts incorporating same
KR100250902B1 (en) Method of producing plants having resistance in cymv

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase